

References for Application for inclusion of paromomycin in the WHO Model List of Essential Medicines

6 (a) Visceral leishmaniasis – disease burden.

Desjeux P. Leishmaniasis: current situation and new perspectives. *Comp Immunol Microbiol Infect Dis* 2004;27:305-18.

Sundar S, Murray HW. Availability of miltefosine for the treatment of kala-azar in India. *Bull World Health Organ* 2005;83:394-5.

6 (b) Inadequacy of existing medicines for VL

Resistance to sodium stibogluconate

Sundar S. Drug resistance in Indian visceral leishmaniasis. *Tropical Medicine and International Health* 2001, 6 (11) 849-54

Sundar S, Murray HW. Availability of miltefosine for the treatment of kala-azar in India. *Bull World Health Organ* 2005;83:394-5.

Rijal S, Chappuis F, Singh R, et al. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. *Trans R Soc Trop Med Hyg* 2003;97:350-4.

Sundar S, Singh VP, Sharma S, Makharia MK, Murray HW. Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. *J Infect Dis* 1997;176:1117-9.

Sundar S, More DK, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. *Clin Infect Dis* 2000;31:1104-7.

Thakur CP, Narayan S, Ranjan A. Epidemiological, clinical and pharmacological study of antimony resistant visceral leishmaniasis in Bihar, India. *Indian J Med Res* 2004;120:166-72.

Das VN, Ranjan A, Bimal S, et al. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar. *Natl Md J India* 2005;18:131-3.

References for Application for inclusion of paromomycin in the WHO Model List of Essential Medicines

Pentavalent antimonials - Reviews of antimonial use

Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. *Clin Infect Dis.* 1997;24:684-703.

Herwaldt BL; Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. *Am J Trop Med Hyg.* 1992;46:296-306

Pancreatic, Cardiac and Other Antimonial Toxicity

Delgado J, Macias J, Pineda JA, Corzo JE, Gonzalez-Moreno MP, de la Rosa R, Sanchez-Quijano A, Leal M, Lissen E. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. *Am J Trop Med Hyg.* 1999;61:766-9.

Gasser RA Jr; Magill AJ; Oster CN; Franke ED; Grogl M; Berman JD. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. *Clin Infect Dis.* 1994 Jan; 18(1): 83-90

Laguna F, Lopez-Velez R, Pulido F, Salas A, Torre-Cisneros J, Torres E, Medrano FJ, Sanz J, Pico G, Gomez-Rodrigo J, Pasquau J, Alvar J. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. *AIDS.* 1999;13:1063-9.

Hepburn NC; Nolan J; Fenn L; Herd RM; Neilson JM; Sutherland GR; Fox KA. Cardiac effects of sodium stibogluconate: myocardial, electrophysiological and biochemical studies. *QJM.* 1994;87:465-7

References for Application for inclusion of paromomycin in the WHO Model List of Essential Medicines

Mechanisms of antimonial toxicity

Franco MA; Barbosa AC; Rath S; Dorea JG. Antimony oxidation states in antileishmanial drugs. *Am J Trop Med Hyg.* 1995 May; 52(5): 435-7

Deps, P.D.; Viana, M.C.; Falqueto, A.; Dietze, R. Comparative study between sodium stibogluconate BP88 (Shandong Xinhua - China) and meglumine antimoniate (Rhodia - Brazil) on the treatment of cutaneous leishmaniasis, in the endemic area Corte de Pedra, Bahia, Brazil. *Revista da Sociedade Brasileira de Medicina Tropical* 2000;33:535-43.

Sundar S, Sinha PR, Agrawal NK, Srivastava R, Rainey PM, Berman JD, Murray HW, Singh VP. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high osmolarity lot of sodium antimony gluconate. *Am J Trop Med Hyg* 1998;59:139-43

Foetal loss in pregnant women treated with antimonials

Mueller M, Balasegaram M, Koummuki Y, Ritmeijer K, Santana MR, Davidson R. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. *J Antimicrob Chemother.* 2006 Oct;58(4):811-5.

Increased mortality associated with antimonials

Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, Boots G, den Boer M, Davidson RN. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. *Clin Infect Dis.* 2006 Aug 1;43(3):357-64. Epub 2006 Jun 20.

Amphotericin B use and toxicity

Jha TK, Giri YN, Singh TK, Jha S. Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in north Bihar, India. *Am J Trop Med Hyg.* 1995 Jun;52(6):536-8.

Mishra M, Biswas UK, Jha AM, Khan AB. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. *Lancet.* 1994 Dec 10;344(8937):1599-600.

References for Application for inclusion of paromomycin in the WHO Model List of Essential Medicines

Pentamidine use and toxicity

Jha SN, Singh NK, Jha TK. Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial. *J Assoc Physicians India* 1991; 39 : 314-6.

Das VN, Ranjan A, Sinha AN, Verma N, Lal CS, Gupta AK, Siddiqui NA, Kar SK. A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. *J Assoc Physicians India*. 2001 Jun;49:609-13.

Thakur CP, Kumar M, Pandey AK. Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study. *Am J Trop Med Hyg.* 1991 Oct;45(4):435-41.

Visceral leishmaniasis unresponsive to antimonial drugs. II. Response to high dosage sodium stibogluconate or prolonged treatment with pentamidine. Bryceson AD, Chulay JD, Mugambi M, Were JB, Gachihi G, Chungu CN, Muigai R, Bhatt SM, Ho M, Spencer HC, et al. *Trans R Soc Trop Med Hyg.* 1985;79(5):705-14.

Liposomal amphotericin B.

Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J. Liposomal amphotericin B for the treatment of visceral leishmaniasis. *Clin Infect Dis*. 2006 Oct 1;43(7):917-24. Epub 2006 Aug 28.

Miltefosine

Singh RK, Pandey HP, Sundar S. Visceral leishmaniasis (kala-azar): challenges ahead. *Indian J Med Res*. 2006 Mar;123(3):331-44.

Berman J, Bryceson AD, Croft S, Engel J, Gutteridge W, Karbwang J, Sindermann H, Soto J, Sundar S, Urbina JA. Miltefosine: issues to be addressed in the future. *Trans R Soc Trop Med Hyg.* 2006 Dec;100 Suppl 1:S41-4.

Perez-Victoria FJ, Gamarro F, Ouellette M, Castanys S. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from *Leishmania* involved in drug resistance. *J Biol Chem* 2003; 278 : 49965-71.

References for Application for inclusion of paromomycin in the WHO Model List of Essential Medicines

7. Treatment details - SUMMARY OF PRODUCT CHARACTERISTICS (This section comprises the package insert for Paromomycin IM Injection)

8 /9. Comparative effectiveness and safety

Phase 2 studies of paromomycin

Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. *Trans R Soc Trop Med Hyg* 1990; 84:221-5.

Seaman J, Pryce D, Sondorp HE, Moody A, Bryceson AD, Davidson RN. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. *J Infect Dis* 1993;168:715-20.

Thakur, CP, Olliaro P, Gothoskar S, et al. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (=paromomycin) antimonial combinations, a pilot study in Bihar, India. *Trans R Soc Trop Med Hyg* 1992;86:615-6.

Thakur CP, Bhowmick S, Dolfi L, Olliaro P. Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial. *Trans R Soc Trop Med Hyg* 1995;89:219-23.

Thakur CP, Kanyok TP, Pandey AK, et al. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. *Trans R Soc Trop Med Hyg* 2000;94:429-31.

Thakur CP, Kanyok TP, Pandey AK, Sinha GP, Messick C, Olliaro P. Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase II clinical study. *Trans R Soc Trop Med Hyg* 2000;94:432-3.

Jha TK, Olliaro P, Thakur CP, et al. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. *BMJ* 1998;316:1200-5.

References for Application for inclusion of paromomycin in the WHO Model List of Essential Medicines

Phase 3 study:

Interim data presented at the ASTMH meeting Nov 2004 (see attached abstract)

Submitted manuscript (see attached)

Pharmacokinetic data presented at ICAAC 2006 (see attached abstract)